Skip to main content
. 2016 Jun 30;11:1485–1494. doi: 10.2147/COPD.S105948

Table 1.

Demographic, functional, and treatment characteristics of healthy subjects and COPD patients

Characteristics Healthy subjects (n=35) COPD patients (n=51)
Age (years) 57±9 62±10*
Sex, M/F 14/21 33/18
Height (cm) 169±8 169±10
Weight (kg) 74±12 70±18
BMI (kg/m2) 26±3 24±5
Tobacco status (NS/ExS/CS) 14/0/8 0/26/25
Pack-year 5 (0–42) 44*** (10–125)
FeNO (ppb) 18 (6–39) 13* (5–88)
FEV1 pre (mL) 2,986±763 1,517±630***
FEV1 pre (% pred) 106±14 54±18***
FEV1 post (mL) 3,199±885 1,658±701***
FEV1 post (%) 113±15 59±20***
Reversibility (%) 3±3 9±9**
FVC pre (mL) 3,799±968 2,796±924***
FVC pre (%) 111±14 79±19***
FVC post (mL) 3,807±1,113 2,951±990**
FVC post (%) 111±15 84±20***
FEV1/FVC pre (%) 79±4 53±10***
FEV1/FVC post (%) 84±4 55±10***
Oral corticosteroids 0 (0%) 6 (12%)
Inhaled corticosteroids 0 (0%) 33 (65%)
Inhaled corticosteroids (eg, beclomethasone/day) 0 550*** (0–4,000)
LABA 0 (0%) 39 (77%)
Anticholinergics 0 (0%) 29 (57%)
CAT total score 21 (9–34)

Notes: Data are presented as absolute number, absolute number (percentage), mean ± SD, or median (range).

*

P<0.05,

**

P<0.01,

***

P<0.001 vs healthy subjects.

Abbreviations: BMI, body mass index; NS, nonsmoker; ExS, ex-smoker; CS, current smoker; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; pred, predicted; LABA, long-acting beta-agonist; CAT, COPD assessment test; SD, standard deviation; M, male; F, female.